Randomized open label study to compare the efficacy and safety of everolimus followed by chemotherapy with STZ-5FU upon progression or the reverse sequence, chemotherapy with STZ-5FU followed by everolimus upon progression, in advanced progressive pNETs (SEQTOR study)
Treatment period: Estimated length, up to 140 +/- 8 weeks
Arm A: Everolimus+STZ-5FU. An interval period of time between the end of first regime and the start of second regimen ≤ to 4 weeks.
Arm B: STZ-5FU+Everolimus.